Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.

Yokota K, Takenouchi T, Fujisawa Y, Fukushima S, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Han S, Watanabe M, Noguchi K, Yamazaki N

Open source

DOI: 10.1111/1346-8138.17002
Published: 2024 May
Container: The Journal of dermatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/1346-8138.17002,
  title = {Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.},
  author = {Yokota K and Takenouchi T and Fujisawa Y and Fukushima S and Uchi H and Inozume T and Kiyohara Y and Uhara H and Nakagawa K and Furukawa H and Han S and Watanabe M and Noguchi K and Yamazaki N},
  year = {2024},
  journal = {The Journal of dermatology},
  doi = {10.1111/1346-8138.17002},
  url = {https://doi.org/10.1111/1346-8138.17002}
}

RIS

TY  - JOUR
TI  - Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
AU  - Yokota K
AU  - Takenouchi T
AU  - Fujisawa Y
AU  - Fukushima S
AU  - Uchi H
AU  - Inozume T
AU  - Kiyohara Y
AU  - Uhara H
AU  - Nakagawa K
AU  - Furukawa H
AU  - Han S
AU  - Watanabe M
AU  - Noguchi K
AU  - Yamazaki N
PY  - 2024
JO  - The Journal of dermatology
DO  - 10.1111/1346-8138.17002
UR  - https://doi.org/10.1111/1346-8138.17002
ER  -

APA

K, Y., T, T., Y, F., S, F., H, U., T, I., Y, K., H, U., K, N., H, F., S, H., M, W., K, N., & N, Y. (2024). Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.. The Journal of dermatology. https://doi.org/10.1111/1346-8138.17002

Source records

pubmed · retrieved 2026-09-26T15:12:37.587Z
europe-pmc · retrieved 2026-09-26T15:12:37.586Z